|
|
UM-3004 |
|
Vaxjo ID |
204 |
|
Vaccine Adjuvant Name |
UM-3004 |
|
Adjuvant VO ID |
VO_0005353
|
|
Description |
A vaccine adjuvant that includes UM-3004, a small molecule TLR7/8 agonist that can stimulate Th1-biased immune profile |
|
Stage of Development |
Research |
|
Location Licensed |
US (University of Montana) |
|
Host Species for Testing |
Mouse |
|
Components |
Phospholipidated Imidazoquinoline |
|
Storage |
0C |
|
Preparation |
phospholipidation procedure involves a tandem phosphoramidite method |
|
Function |
innate immune activation |
| References |
(Bazin-Lee, 2023): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=46]
Miller et al., 2020: Miller SM, Cybulski V, Whitacre M, Bess LS, Livesay MT, Walsh L, Burkhart D, Bazin HG, Evans JT. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice. Frontiers in immunology. 2020; 11; 406. [PubMed: 32210973].
|
|
